Minerva Rockets On Positive PhIIb Data – Is A Big Pharma Partnership On The Horizon?
Executive Summary
Minerva Neurosciences Inc.'s schizophrenia drug that targets patients with negative symptoms, an indication with high unmet need and no approved treatments, has met primary and secondary endpoints in a Phase IIb trial – positioning the company well for access to an open market and marking it as an attractive M&A target.
You may also be interested in...
Forum's Lead Drug Program Fails In Phase III Schizophrenia Trials
Forum Pharmaceuticals' lead compound encenicline has failed to meet the endpoints in two Phase III trials for the treatment of cognitive impairment in schizophrenia patients. .
Finding Value Left On The Shelf: Karuna Case Study
PureTech’s gamble to take an older Eli Lilly drug off the shelf to redevelop in a new indication paid off. The company aims to replicate this 'Karuna model' in the near future.
Podcast: NodThera On The Role Of The Brain In Driving Chronic Disease
Alan Watt, CEO of NodThera, a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, talks to In Vivo about the company’s pipeline and recent data publication in the field of obesity.